Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5484_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Contents
- •1.3.2 Solubility Parameters
- •1.1 Introduction
- •1.2 Types of Drug Action Theories
- •1.2.1 The Ferguson Principle
- •1.2.2 Structure and Activity
- •1.2.3 Relationship between Molecular Structure and Biological Action
- •1.3 Physicochemical Parameters and Pharmacological Activity
- •1.3.1 Introduction
- •1.3.3 Steric Parameters
- •1.4 Stereochemistry Consideration
- •1.4.1 Chirality
- •1.4.2 Stereochemistry and Drug Action
- •1.4.3 Isomers Types
- •1.5 Isosterism and Bioisosterism
- •1.5.1 Pharmacophore or Lead
- •1.5.2 Isosteres
- •1.5.3 Bioisosteres
- •1.6 Drug-Receptor Interaction
- •1.6.1 Receptor
- •1.6.2 Requirement for Agonist Activity
- •1.6.3 Receptor Families
- •1.6.4 Role of Chemical Bonding
- •1.6.5 Types of Receptors
- •1.7 Prodrugs
- •1.7.1 Introduction
- •1.7.2 Concept of Prodrug
- •1.7.3 Prodrugs are Designed for the Following Purposes
- •1.7.4 Classification of Prodrugs
- •Exercise
- •Autonomic Nervous System
- •2.1 Introduction
- •2.2 Cholinergic Drugs
- •2.2.1 Definition
- •2.2.2 Cholinergic Receptors
- •2.2.3 Biosynthesis of Ach
- •2.2.4 Classification
- •2.2.5. Action of Cholinesterase Inhibitors
- •2.2.6 Structural Activity Relationship (SAR) of Musarinic Agonist/Cholinomimetics
- •2.2.7 Cholinomimetic Agents
- •2.2.9 Classification of Anticholinergic Agents
- •2.2.10 Structural Activity Relationship (SAR) of Anticholinergic Agent
- •2.2.11 Anticholinergic Agent
- •2.2.12 Newer Drug
- •2.3 Adrenergic Agents
- •2.3.1 Introduction
- •2.3.2 Mechanism of Action
- •2.3.3 Biosynthesis of Catecholamines
- •2.3.4 Pharmacological Action
- •2.3.5 Adrenergic
- •2.3.6 Classification
- •2.3.7 SAR of Phenylethanolamine Derivatives/Direct Acting Agonist
- •2.3.8 SAR of Indirect Acting Agonist/Arylethylamine Derivatives
- •2.3.9 Adrenergic Agents
- •2.3.10 Newer Drugs
- •Exercise
- •3.1 Introduction
- •3.2 Ideal Characteristics of General Anaesthetics
- •3.4 Concepts of Mechanism of Anaesthesia
- •3.5 Minimum Alveolar Concentration (MAC)
- •3.6 Stages of Anaesthesia
- •3.7 Classification of General Anaesthesia
- •3.8 Receptors Involved in the Mechanism
- •3.9 Stereochemistry of Volatile Anaesthetics
- •3.10 Toxicity of Fluorinated General Anaesthetics
- •3.11 General Anaesthetics Agents
- •3.12 Newer Agents
- •Exercise
- •4.1 Introduction
- •4.2 Methods of Administration
- •4.3 Classification of Local Anaesthetics
- •4.4 Mechanism of Action of Local Anaesthetics
- •4.6 Local Anaesthetic Agents
- •4.7 Newer Agents
- •Exercise
- •5.1 Introduction
- •5.3 Classification of Sedative and Hypnotics
- •5.3.1 Barbiturates
- •5.3.2 Benzodiazepines
- •5.3.3 Halogenated Sedative and Hypnotics
- •5.3.4 Heterocyclic Sedative and Hypnotics
- •5.3.5 Miscellaneous Sedative and Hypnotics
- •5.4 Mechanism of Action
- •5.5 Barbiturates
- •5.5.1 General Synthetic Approach of Sedative and Hypnotics
- •5.6 SAR of (Barbiturates) Sedative and Hypnotics
- •5.7 Benzodiazepines
- •6.7 Morphines and Derivatives
- •5.8 SAR of Benzodiazepines
- •5.9 Heterocyclic Sedative and Hypnotics
- •5.10 Halogenated Sedative and Hypnotics
- •5.11 Recent Development of Sedative and Hypnotics
- •Exercise
- •6.1 Introduction
- •6.2 Opioid Receptors
- •6.3 Opioid Peptides
- •6.4 Classification
- •6.5 Mechanism of Action (Signal Transduction)
- •6.6 Central Side Effects of Opioid Analgesics
- •6.8 SAR of Morphines Derivatives
- •6.9 Piperidine Derivatives
- •6.10 SAR of Piperidines Derivatives
- •6.11 Diphenyl Haptanones Derivatives (Acyclic Analgesics)
- •6.12 SAR of Diphenyl Haptanone Derivatives
- •6.13 Benzazocin Derivatives/Morphan Derivatives
- •6.14 Narcotics Antagonists/Opioid Antagonists
- •6.15 Newer Drugs
- •6.16 Antitussive Agents
- •Exercise
- •7.1 Introduction
- •7.2 Classification of Epilepsy
- •7.3 Seizure Initiation and Propagation
- •7.4 Receptors Involved in the Mechanism
- •7.5. Classification of Antiepileptic Agnents
- •7.5.1 Ureid Derivatives/First Generation Antiepileptic Agents
- •7.5.2 Benzodiazepines
- •7.5.3 Urea and MonoAcyl Urea-Derivatives/Iminostilbenes
- •7.5.4 Miscellaneous Agents
- •7.6 Hydantoins Agents
- •7.7 Oxazolidinediones Agents
- •7.8 Succinimides Agents
- •7.9 Iminostilbens Agents
- •7.10 Aliphatic Acid Agent
- •7.11 Second Generation Antiepileptic Drugs
- •7.12 Other Miscellaneous Antiepileptic Agents
- •7.13 Models Requirements for Antiepileptic Agents/SAR
- •7.14 Newer Drugs Development
- •Exercise
- •8.1 Introduction
- •8.2 Etiology of Parkinson
- •8.3 Initiation of Therapy
- •8.4 Classification of Antiparkinsonism Agents
- •8.4.1 Dopaninergic Treatment
- •8.4.2 Agents Action on Nondopaminergic System
- •8.5 Dopaminergic Agents
- •8.6 Non-Dopaminergic Agents
- •8.7.1 Conformational Aspects
- •8.7.2 PKa Aspects
- •Exercise
- •9.1 Introduction
- •9.2 Clinical Uses of CNS Stimulants
- •9.3 Classification
- •9.4 Mechanism of Action
- •9.5 CNS Stimulants Agents
- •9.5.1 Amphetamine Related Agents
- •9.5.2 SAR or Structural Requirements of Amphetamines
- •9.5.3 Xanthine Alkaloids
- •9.5.4 Cocaine Related CNS stimulating Agents
- •9.5.5 Miscellaneous CNS Stimulants Agents
- •9.5.6 Newer Agents
- •9.6 Metabolic Patterns of Some CNS Stimulants Agents
- •9.7 Analeptics or Respiratory Stimulants
- •Exercise
- •10.1 Introduction
- •10.2 Causes of Schizophrenia
- •10.2.1 Adverse Effects
- •10.3 Antipsychotic Agents
- •10.3.1 Mechanism of Action
- •10.4 Classification
- •10.5 Tricyclic Neuroleptics/Phenothiazines
- •10.5.1 Phenothiazines Structure and Structure Activity Relationship
- •10.5.2 Specific Derivatives
- •10.6 Thioxanthene Derivatives
- •10.7 Dibenzoxazepine and Dibenzdiazepine Derivatives
- •10.8.1 SAR of Butyrophenones
- •10.8.2 Butyrophenones Agents
- •10.9 Benzamides Derivatives
- •10.9.1 Structure Activity Relationship of Benzamides
- •10.9.2 Specific Derivatives
- •10.10 Dihydroindolone Derivative
- •10.11 Diphenylbutylpiperidine Derivatives
- •10.12 Miscellaneous Agents
- •10.13 Newer Agents
- •Exercise
- •11.1 Introduction
- •11.2 Management of Depression
- •11.3 Classification
- •11.4 Tricyclic Antidepressants
- •11.4.1 Mechanism of Action
- •11.4.2 Structural Activity Relationship (SAR) of Tricyclic Antidepressants (TCAs)
- •11.4.3 Metabolic Pattern of Tricyclic Antidepressants
- •11.4.4 Specific Drugs
- •11.6 Specific Drugs
- •11.7 Selective Serotonine Reuptake Inhibitors (SSRI)
- •11.7.1 Mechanism of Action
- •11.7.2 Structure Activity Relationship (SAR) of (SSRIs)
- •11.7.3 Specific Drugs
- •11.8 Newer Atypical Antidepressants
- •11.8.1 Specific Drugs
- •11.9 Newer Agents
- •Exercise
- •12.1 Introduction
- •12.2 Causes of Anxiety
- •12.2.1 Receptor Involve
- •12.3 Classification
- •12.4 Benzodiazepines
- •12.4.1 Mechanism of Action
- •12.4.2 Metabolic Pattern
- •12.5 Structure Activity Relationship (SAR) of Benzodiazepines
- •12.6 Benzodiazepines Derivatives (Specific Drugs)
- •12.7 Non-benzodiazepine Derivatives (Specific Drugs)
- •12.8 Newer Agents
- •Exercise
- •13.1 Introduction
- •13.2 Mechanism of Action
- •13.3 Classification
- •13.4 Specific Derivatives
- •13.4.1 Glycerol Monoethers Derivatives
- •13.4.2 Alkanediols Derivatives
- •13.4.3 Benzazole Derivative
- •13.4.4 Imidazolin Derivative
- •13.4.5 Miscellaneous Agents
- •13.5 Newer Agents
- •Exercise
- •14.1 Introduction
- •14.2 Mechanism of Action
- •14.3 Classification
- •14.4 Non-depolarizing Muscle Relaxants
- •14.5 Structural Activity Relationship of Aminosteroids NMB Agents
- •14.6 SAR of Tetrahydroisoquinoline Derivatives
- •14.7 Depolarizing Muscle Relaxants (DPR)
- •14.8 SAR of Depolarizing Muscle Relaxants
- •14.9 Newer Agents
- •Exercise
- •15.1 Introduction
- •15.2 Nomenclature of Heterocyclic Compounds
- •15.3 Naming of Heterocyclic Rings
- •15.4 Nomenclature of Fused Ring System
- •Exercise
- •References
- •Index

Skeletal Muscle Relaxants 205
13
Skeletal Muscle Relaxants
13.1 INTRODUCTION
Skeletal muscle relaxants are also known as “spasmolytic” agents. Spasticity of muscles is
characterized by the spasms of skeletal muscles in order to increase in tonic stretch reflexes and
muscles weakness. It is associated with cerebral palsi, multiple sclerosis, spinal cord injury, etc.,
results of hyperexcitability of motor neurons. Clinically, spasm is also associated with severe pain in
patient. Spasmolytic drugs or skeletal muscles relaxants relax the skeletal muscles and act as analgesia
both. The first medicinal agent was recognized to show spasmolytic activity, Antodyne or 3-Phenoxy-
1-2-Propaindiol in 1910. Antodyne acts as an analgesic and antipyretic but duration of action of
spasmolytic activity was too short to be clinically useful. Later in 1943, glycerylethers related
antodynes were made a new series of skeletal muscle in relaxants, mephenesin was discovered in
1946 that had ability to depress postsynaptic spinal cord reflexes.
Many CNS depressant agents cause muscle relaxation in the treatment of sprains, ruptures,
arthritis and various muscular disturbances.
13.2 MECHANISM OF ACTION
Skeletal muscle relaxants are functioning to the GABAergic system to depress the skeletal muscles
activity. They decrease the tone of spasticiy via hyperpolarization of G Protein activated K
+
channel.
Some compounds, e.g., orphenadrine acts on NMDA receptors and exhibit antagonist action
(antimuscarinic activity). Cyclobenzaprine drug show muscles relaxant action through antagonism
action on Serotonin 5H T
2
receptors in descending neurons of spinal cord.

206 A Textbook of Medicinal Chemistry
13.3 CLASSIFICATION
A. Glycerol Monoethers Derivatives:
1. Mephenesin (Tolserol®)
HC
3
CH OH
2
CH — OH
HCO
2
2. Carbamol
CH —O—C—NH
22
CH — OH
HC—O
2
R
2
O
R
1
R
1
= H, R
2
= Cl Chlorphenesin (Maolate®)
R
1
= OCH
3
,
R
2
H Methocarbamol (Robaxin®)
Fig. 13.1
B. Alkanediols Derivatives:
1. Meprobomate (Equanil®)
CH —O—C—NH
22
CH —C—C H
337
CH —O—C—NH
22
O
O
2. Carisoprodol (Rela®)
CH —O—C—NH
22
HC—C—C H
337
CH — O — C — NHCH
2
O
O
CH
3
CH
3

Skeletal Muscle Relaxants 207
3. Metaxolone (Skelaxin®)
H
HC—N
2
C O
CH — O
HC—O
3
CH
3
CH
3
Fig. 13.2
C. Benzazole Derivative:
1. Chlorzoxazone (Paraflex®)
Cl
C O
N
H
O
Fig. 13.3
D. Imidazoline Derivative:
1. Dantrolene (Dantrium®)
CH N — N
O
ON
2
NH
O
O
Fig. 13.4
E. Miscellaneous:
1. Orphanadrine citrate (Norflex®)
CHO — CH — CH — N
22
CH
3
CH
3
CH
3
2. Cyclobenzaprine (Flexaril®)
CH — CH — CH — N
2
CH
3
CH
3
2

208 A Textbook of Medicinal Chemistry
3. Baclofen (Lioresal ®)
Cl
CH — NH
22
CH
CH — COOH
2
Fig. 13.5
4. Benzodiazepines : Diazepam, Fletazepam (Discused in Chapter 12)
13.4 SPECIFIC DERIVATIVES
13.4.1 Glycerol Monoethers Derivatives
1. Mephenesin (Tolserol
®
): is 3-(o-methyl phenoxy)-1,2-Propanediol
CH
2
O — CH — CH — CH OH
22
OH
Fig. 13.6
Mephenesin is a potent skeletal muscle relaxant. It cause the skeletal muscle relaxation of hyper
tonic muscles to minimize the sensory stimuli. It is also significantly depressed the superficial
reflexes. Mephenesis is suggested to the treatment of muscular spasm, hyperkinetic condition. It is
also used in the treatment of anxiety and tension states.
Synthesis:
CH
3
ONa
+ Cl — CH — CH — CH — OH (condensation)
22
C
CH
3
O — CH — CH — CH OH
22
Sodium-O-Cresolate
a-chlorhydrin Mephenesin
2. Chlorphenesin (Maolate
®
):- 3-(p-chlorophenoxy)-1, 2-propanediol-1-carbamate
Cl
O — CH — CH — CH — O CO NH
222
OH
Fig. 13.7
Chlorphenesin is a potent spasmolytic agent, due to presence of secondary hydroxyl group. It
undergoes active metabolism via glucoronidation. Chlorphenesis is used for the symptomatic relief
of muscular spasm as well as it exhibits antifungal activity.

Skeletal Muscle Relaxants 209
Synthesis:
OH
Cl
OH + Cl — CH — CH — CH OH
22
Cl
OCH — CH — CH — OH
22
OH
Phosgene
P-chlorophenol
1-chloropropan-2, 3-diol
Cl
Chlorphenesin carbamate
O—CH —CH—CH —O—C
22
O
OH
NH
2
Cl
OCH —CH—CH —O—C—Cl
22
O
NH
3
OH
Fig. 13.8
3. Methocarbamol (Robaxin
®
): 3-(O-methoxy phenoxy)-1, 2-propandiol-1-carbamate
OCH — CH — CH — OCONH
222
OH
OCH
3
Fig. 13.9
Methocarbamol is potent centrally acting muscles relaxant. It significantly relieves from muscles
spasm. It is also used in the treatment of Parkinson’s disease.
Synthesis:
OH
+ Cl — CH — CH — CH OH
22
O — CH — CH — CH OH
22
OH
Phosgene
Catechol monomethyl
ether
1-chloropropane-2, 3
diol
Methocarbamol
OCH —CH—CH —O—C—NH
22 2
O
OH
OCH —CH—CH —O—C—Cl
22
O
NH
3
OH
OH
OCH
3
Alkylation
Amination
OCH
3
OCH
3
OCH
3
Fig. 13.10
13.4.2 Alkanediols Derivatives
1. Maprobamate (Equanil®): 2-methyl-2-propyl-1,3-propandiol dicarbamate.

210 A Textbook of Medicinal Chemistry
H N — CO — O — H C — C — CH — O — OCNH
2222
CH
3
CH CH CH
223
Fig. 13.11
Maprobamate is generally sedative and hypnotics. It is believed that its action exerts on particular
area of brain in respect of conductivity. It shows anticonvulsant activity beside that muscles relaxant
activities. It is also used as a mild to moderate tranquilizer in the treatment of anxiety and mental
disorder.
Synthesis:
HOH C — C — CH OH
22
CH
3
CH CH CH
223
ClCOOH C — C — CH OOCCl
22
CH
3
CH
37
2-methyl-2-m-propyl-1-,3-propandiol Chloroformate diester
(Ammonolysis)
Maprobamate
Toluene/Phosgene 0°C
N, N-Dimethyl aniline
Fig. 13.12
5. Metaxolone (Skelaxin®):- 5-[(3,5-xylyloxy)Methy)]-2-oxazolidinone
Metaxolone significantly reduces the muscle tone. It is used for the relief of acute muscle spasms
caused by various injuries or strains.
Synthesis:
Cl
Cl
OH
+ Cl — CH — CH — CH OH
22
OH
Cl
Cl
O — CH — CH — CH OH
22
OH
Alkylation
HC
3
HC
3
O—CH
2
O
O
N
H
NH
2
(i)
(ii) Alkylation
C O
NH
2
1-Chloropropane-2,3-diol
3,5-Dichlorophenol
Metaxalone
(Urea)
Fig. 13.13

Skeletal Muscle Relaxants 211
13.4.3 Benzazole Derivative
1. Chlorzoxazone (Paraflex
®
):- 5-chloro-2-benzoxalinone
Chlorzoxazone is a potent centrally acting skeletal muscle relaxant. It inhibits the postsynaptic
reflexes both within spinal cord and subcortical area of brain. It is used in the treatment of severe
painful muscle spasm. It is also suggested in the treatment of spondilytis, sprains and muscles
strains.
Synthesis:
Cl
NH
2
OH
Cl
O
N
|
H
O
COCl
2
Phosgene
2-amino-4-chlorophenol
Chlorzoxazone
Fig. 13.14
13.4.4 Imidazolin Derivative
2. Dantrolene (Dantrium
®
): 1-[[5-(p-Nitrophenyl)-furfulidene]-amino]-hydantoin sodium salt
hydrate.
Dantrolene is hydantoin derivative which acts centrally and peripherally to reduce spasticity.
Dantrolene is used in the treatment of spinal cord injury. Stroke cerebral palsy and multiple sclerosis.
O
N
NH
Na
O
CH N
–
+
ON
2
O
Fig. 13.15
13.4.5 Miscellaneous Agents
Beclofen (±) (Lioresa
®
): β-(aminomethyl)-p-chlorohydro-cinnamic acid.
Beclofen is the derivative of gamma aminobutyric acid because it is structurally similar to GABA.
H N — H C — CHCH COOH
22 2
Cl
Fig. 13.16

212 A Textbook of Medicinal Chemistry
Thus, it shows agonist activity at the size of GABA
B
receptor via mechanism G-Protein activated
K
T
channel (hyperpolarization). Beclofen is one of the most common used antispastic drugs. Beclofen
is employed by oral administration and has minimum hepatic metabolism. It is also given to the
patient via parentral and intrathecal administration.
Synthesis:
Cl
CH CH — COOC H
25
Cl
CH NO
32
Nitromethane
CH — NO
22
CH
H C — COOC H
225
(Ester derivative)
Reduction
[H]
Cl
CH — NH
22
CH
CH — COOC H
225
NaOH
Cl
CH — NH
22
CH
H C — COOH
2
Beclofen
4-chlorocinnamic acid
Fig. 13.17
13.5 NEWER AGENTS
1. MS-322 : (R)-(+)-3-phenyl-5-2-(1-pyrrolidinyl methyl)-butyryl isoxazole hydrochloride.
Recent studies on centrally acting muscle relaxants depicted a newer agent MS-322 that reduced
spinal reflex potential in acutely spinalized rats close dependently. It shows inhibitory effects on
Polysynaptic and dorsal root reflexes were more marked than monosynaptic reflexes therefore it
shows better muscle relaxant activity.
N
O
N
O
C
H
CH
3
HCl
Fig. 13.18
2. Silperisone: N-[(dimethyl-4-fluorobenzyl silyl)-methyl]-piperidine HCl.
Silperisone is organo silicon compound with centrally acting muscles relexant activity. Studies
showed that silpersone cause CNS depressant or motorside effect than other drug tolperisone. It is
an effective to suppress monosynaptic and postsynaptic spinal reflexes.
1
General Pharmacology (1998) The Vascular System, Vol. 30 (3), 393-398.

Skeletal Muscle Relaxants 213
F
CH
3
CH — Si — CH — N
22
CH
3
HCl
Fig. 13.19
3. Tolperisone: 2-methyl-1-(4-methyl phenyl)-3(1-piperidyl)-propane-1-one
Tolperisone is potent centrally acting muscles relaxant it is much more suitable for cerebral
atherosclosis for better movement for treating extra piramidal movement disorders.
N
HCl
HC
3
O
CH
3
Fig. 13.20
4. Lamperison .HCl (NK-433): (–)-(R)-2-methyl-3-(1-pyrrolidinyl)-4’-tri-fluoromethyl
propiophenone monohydrochloride.
It is a novel centrally acting muscle relaxant which inhibits monosynaptic tonic vibration reflex.
but it is a weak inhibitor on post-synaptic reflexes.
F—C—F
C O
N
F
HC
3
Fig. 13.21
EXERCISE
1. Define spasmolytic agents or centrally acting muscle relaxants.
2. Classify centrally acting muscle relaxants and explain their mechanism of action.
2
CNS—Reviews.(2006), Vol. 12 (3-4), 218–235.
3
Ozawa et al. (1996) Eur. J. Pharmacol. 298 (1) 57, 62

214 A Textbook of Medicinal Chemistry
3. Write the synthesis and MOA with their uses of Glycerol monoether derivatives.
4. Classify alkanediol derivatives of skeletal muscles relaxants. Give their mechanism of action
and uses.
5. Write following drugs synthesis.
1. Beclojen
2. Mephensin
3. Chlorzoxazone
4. Metaxolone
6. What are the recent developments in skeletal muscles relaxants? Explain it.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
